New Report Covers Serine/Threonine-Protein Kinase Chk1Checkpoint Kinase 1-Pipeline Review, H1 2016

Serine/Threonine-Protein Kinase Chk1Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Serine/Threonine-Protein Kinase Chk1Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- The report reviews Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) development landscape 

Companies Mentioned

CanBas Co., Ltd. Cascadian Therapeutics Inc Eli Lilly and Company Genentech, Inc. Sareum Holdings Plc Vernalis Plc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###